Sugi Predict

Sugi Predict / Compounds / SCHEMBL20673881

SCHEMBL20673881

SCHEMBL20673881

NS(=O)(=O)c1nc(O)n2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BAZ2B Q9UIF8 2/20 0.36
▸ BAZ2A Q9UIF9 2/20 0.36
▸ MAP2K3 P46734 2/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ CA1 P00915 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ CA12 O43570 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ MAPK14 Q16539 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20674153 0.83 BAZ2B (0.41) BAZ2BBAZ2AMAP2K3KDM4EALDH1A1
SCHEMBL20674162 0.81 BAZ2B (0.37) BAZ2BBAZ2AKDM4EALDH1A1MEN1
SCHEMBL9516992 0.80 KDM4E (0.37) MAP2K3PTGS2CA1CA2CA12
SCHEMBL20674623 0.73 LDHA (0.36) BAZ2BBAZ2AMAP2K3PTGS2PTGS1
SCHEMBL20674161 0.71 MAP2K3 (0.46) BAZ2BBAZ2AMAP2K3PTGS2PTGS1
SCHEMBL20673890 0.70 ADORA3 (0.39) BAZ2BBAZ2AKDM4EALDH1A1HPGD
SCHEMBL20674504 0.69 PTPN1 (0.56) BAZ2BBAZ2AKDM4EALDH1A1HPGD
SCHEMBL20674505 0.69 ALDH1A1 (0.56) BAZ2BBAZ2AMAP2K3KDM4EALDH1A1
SCHEMBL20674150 0.68 BAZ2B (0.46) BAZ2BBAZ2APTGS2PTGS1KDM4E
SCHEMBL20674156 0.67 HIF1A (0.43) BAZ2BBAZ2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LIMITED (KY) 2020-04-30 — — US disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 BAZ2B 583/4885BAZ2A 816/4885MAP2K3 224/4885
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 BAZ2B 681/4885BAZ2A 991/4885MAP2K3 202/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 BAZ2B 583/4885BAZ2A 816/4885MAP2K3 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback